share_log

Philip Morris Battles Low Cigarette Volumes, Pricing Aids

Philip Morris Battles Low Cigarette Volumes, Pricing Aids

菲利普莫里斯與低捲菸銷量作鬥爭,定價援助
Zacks Equity Research ·  2020/01/17 00:00

In the wake of declining cigarette volumes due to stern regulations and consumers’ rising health consciousness, Philip Morris International Inc. (PM-Free Report) has been focused on making its way through strong pricing and reduced risk products (RRPs).

在由於嚴格的規定和消費者健康意識的提高導致捲菸數量下降的情況下, 菲利普莫里斯國際公司Inc.(PM-免費報告)一直專注於通過強勁的定價和降低風險的產品(RRP)取得成功。

Declining Cigarette Volumes a Concern

捲菸銷量下降令人擔憂

Declining cigarette sales volume has been taking a toll on Philip Morris’ performance. Although the metric was flat year over year in first-quarter 2019, the same declined almost 3.6% and 5.9% in the second and third quarters, respectively. We note that cigarette shipment volumes are being adversely impacted by lower demand for cigarettes, stemming from anti-tobacco campaigns and consumers’ rising health consciousness.

捲菸銷售量的下降一直在影響菲利普莫里斯的業績。儘管該指標在2019年第一季度同比持平,但在第二季度和第三季度分別下降了近3.6%和5.9%。我們注意到,由於反煙草運動和消費者健康意識的提高,對捲菸的需求下降,對捲菸發貨量造成了不利影響。

Moreover, the tobacco industry has been facing many challenges as governments around the world are imposing restrictions on tobacco companies, which in turn are lowering cigarette consumption. The U.S. Food and Drug Administration (FDA) has made it mandatory for tobacco companies to use precautionary labels on cigarette packets to dissuade customers from smoking.

此外,隨着世界各國政府對菸草公司施加限制,進而降低捲菸消費,菸草行業一直面臨着許多挑戰。美國食品和藥物管理局(FDA)強制要求菸草公司在香菸包裝上使用預防性標籤,以勸阻顧客吸菸。

In fact, per court orders, Reynolds American along with Altria Group (MO-Free Report) and other cigarette makers has been directed to put up self-critical advertisements on television and newspapers to dissuade customers from smoking. To add to the woes, the FDA is now bent on drastically reducing nicotine in cigarettes to minimally addictive levels. Also, the FDA had raised concerns regarding the consumption of e-cigarettes among the youth. Apart from these, the FDA had earlier announced that tobacco makers must seek marketing authorization for any tobacco product introduced after Feb 15, 2007. The law was extended by the agency to include e-cigarettes, pipe tobacco, cigars and hookah.

事實上,根據法庭命令,雷諾茲美國人和奧馳亞集團(Mo-Free Report)和其他捲菸製造商被指示在電視和報紙上張貼自我批評的廣告,以勸阻顧客吸菸。雪上加霜的是,FDA現在致力於將香菸中的尼古丁大幅降低到最低成癮水平。此外,FDA還提出了對年輕人消費電子煙的擔憂。除此之外,FDA早些時候宣佈,菸草製造商必須為2007年2月15日之後推出的任何菸草產品尋求營銷授權。該機構將這項法律擴大到包括電子煙、菸斗菸草、雪茄和水煙。

Growth Efforts Underway

增長努力正在進行中

Rising health consciousness has pushed consumers toward low-risk RRP’s. With radical investments toward research and development in the RRPs category, Philip Morris is pioneering the shift from harmful tobacco products to scientific and low-risk alternatives. In fact, the company’s IQOS, a smokeless cigarette, is counted among one of the leading RRPs in the industry. The company expects such advanced and high-quality products to help adult smokers switch from traditional cigarettes to smoke-free options. In fact, strong growth in IQOS boosted revenues in the RRPs unit, which increased almost 63.4% to $1,344 million in the third quarter.

健康意識的提高推動消費者轉向低風險的RRP。菲利普莫里斯公司(Philip Morris)在RRP類別的研發上進行了激進的投資,引領了從有害菸草產品向科學和低風險替代品的轉變。事實上,該公司的iQOS,一種無煙香菸,被認為是業內領先的RRP之一。該公司希望這種先進和高質量的產品能幫助成年吸菸者。交換機從傳統香菸到無煙選擇。事實上,iQOS的強勁增長提振了RRPS部門的收入,該部門第三季度的收入增長了近63.4%,達到13.44億美元。

Going ahead, the company expects consistent growth in IQOS and Heated Tobacco categories, and therefore, remains committed to expanding these product lines. Philip Morris has also been undertaking plant conversions, transforming them from cigarette to RRPs manufacturing facilities. Among other initiatives, Philip Morris inked a deal with Canada-based Parallax that provides low-risk tobacco alternatives.

展望未來,該公司預計iQOS和加熱菸草類別將持續增長,因此將繼續致力於擴大這些產品線。菲利普莫里斯也一直在進行工廠改造,將工廠從捲菸廠改造成RRP製造廠。在其他舉措中,菲利普莫里斯與加拿大的Parallax簽署了一項協議,提供低風險的菸草替代品。

Apart from this, Philip Morris has been making efforts to remain afloat and generate revenues with higher cigarette pricing. Though higher pricing might lead to a decline in cigarette consumption, it is seen that smokers tend to absorb price increases owing to the addictive quality of cigarettes. Evidently, higher pricing at the combustible tobacco portfolio has been aiding the company’s performance for a while. In fact, higher pricing variance was an upside to the company’s performance across several regions during the third quarter of 2019. The company continues to expect pricing as the key growth driver in the near term.

除此之外,菲利普莫里斯一直在努力維持運營,並通過更高的捲菸價格創造收入。雖然更高的價格可能會導致捲菸消費的下降,但可以看出,由於香菸的上癮性質,吸菸者往往會吸收價格上漲的影響。顯然,可燃菸草產品組合的較高價格已經幫助該公司實現了一段時間的業績。事實上,較高的定價差異是該公司2019年第三季度在幾個地區的業績的一個上行方面。該公司繼續預計,定價將成為近期關鍵的增長動力。

All said, let’s see how far these initiatives can help Phillip Morris completely offset the aforementioned woes. Notably, the Zacks Rank #3 (Hold) stock has gained 4% in the past six months, underperforming the industry’s growth of 8.7%.

所有人都説,讓我們看看這些舉措能在多大程度上幫助菲利普·莫里斯完全抵消上述困境。值得注意的是,Zacks Rank#3(持有)的股票在過去六個月裏上漲了4%,表現遜於行業8.7%的增長。

Don’t Miss These Solid Picks

不要錯過這些可靠的選擇

Vector Group (VGR-Free Report) , with a Zacks Rank #1 (Strong Buy) has an impressive earnings surprise record. You can see the complete list of today’s Zacks #1 Rank stocks here.

向量組(VGR-Free Report),擁有Zacks排名第一(強力買入)的公司有着令人印象深刻的收益意外記錄。你可以看到這裏是今天ZACKS排名第一的股票的完整名單。

Constellation Brands Inc (-) , with a Zacks Rank #2 (Buy), also has a robust earnings surprise record.

星座品牌Inc.(-),擁有Zacks Rank#2(買入),也有強勁的收益令人驚訝的記錄。

7 Best Stocks for the Next 30 Days

7未來30天的最佳股票

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”

剛剛發佈:專家從目前220只Zacks排名第一的強買入股票名單中精選出7只精英股票。他們認為這些股票行情“最有可能是早期的價格上漲。”

Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.

自1988年以來,這份完整的榜單以平均每年+24.6%的速度超過了市場兩倍多。因此,一定要立即關注這些親手挑選的7個人。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論